title: [Safety of ciprofibrate. Open study in a Portuguese population].
abstract: OBJECTIVE
  To determine the safety of ciprofibrate in portuguese patients with dyslipidaemia.
  
  
  METHODS
  Open-label study with 6-month therapy.
  
  
  METHODS
  Sequential sample of 40 patients, 20 from each hospital, 37 patients (92.5%) completed the study.
  
  
  METHODS
  After at least one month of diet or washout period, all participants were given 100 mg/day of ciprofibrate, taken after the evening meal. Analysis and clinical examinations were performed at weeks (-4), (0), (+8), (+16) and (+24). Glycemia, uric acid, creatine kinase, creatinine and transaminases were determined.
  
  
  RESULTS
  Thirty-seven patients ended the study (92.5%), three abandoned because of gastrointestinal adverse effects, six other patients also complaint of gastrointestinal side effects. The creatinine and creatine kinase levels increased 9.7% and 19.2%, although kept in the normal range. There were no statistically significant changes in glycemia, uric acid and transaminases levels.
  
  
  CONCLUSIONS
  These results confirm the high safety of ciprofibrate in patients with dislipidaemia. The short term of this study does not allows taking conclusions about long term use of this drug.
authors.affiliation: Centro Hospitalar de Coimbra (CHC), Serviço de Medicina Interna.
authors.forename: M C
authors.initials: MC
authors.lastname: Branco
authors.forename: J P
authors.initials: JP
authors.lastname: de Moura
authors.forename: M
authors.initials: M
authors.lastname: Pereira
authors.forename: L C
authors.initials: LC
authors.lastname: Jesus
authors.forename: A
authors.initials: A
authors.lastname: Ferraz
authors.forename: J M
authors.initials: JM
authors.lastname: Silva
authors.forename: M R
authors.initials: MR
authors.lastname: Ferreira
authors.forename: P
authors.initials: P
authors.lastname: Serra e Silva
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D058607:Fibric Acids; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011174:Portugal
chemical_list: D058607:Fibric Acids; D000960:Hypolipidemic Agents; D002995:Clofibric Acid; C019304:ciprofibrate
vernacular_title: Segurança do ciprofibrato. Estudo aberto numa população portuguesa.